SCHEMBL486329

SCHEMBL486329

Cc1cc(=O)n(-c2ccc(C(C)C)cc2)[nH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.65
MAPT P10636 6/20 0.65
KDM4E B2RXH2 5/20 0.65
KMT2A Q03164 5/20 0.65
GAA P10253 2/20 0.65
HTT P42858 2/20 0.65
MEN1 O00255 2/20 0.65
ALKBH5 Q6P6C2 3/20 0.63
LMNA P02545 3/20 0.61
RECQL P46063 2/20 0.61
SMN1; SMN2 Q16637 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
MGLL Q99685 1/20 0.44
POLB P06746 2/20 0.42
ALPL P05186 1/20 0.41
ALKBH3 Q96Q83 1/20 0.40
KDM5A P29375 1/20 0.39
KDM2B Q8NHM5 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8166341 0.82 ALDH1A1 (0.69) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL486340 0.82 ALDH1A1 (0.69) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL486125 0.82 MAPT (0.73) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL8592651 0.79 ALDH1A1 (0.69) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL5203012 0.79 ALDH1A1 (0.69) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL486233 0.79 ALDH1A1 (0.69) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL28264294 0.79 MAPT (1.00) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL5425653 0.78 ALDH1A1 (0.68) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL9150171 0.78 ALDH1A1 (0.68) ALDH1A1MAPTKDM4EKMT2AGAA
SCHEMBL34121 0.78 ALDH1A1 (0.68) ALDH1A1MAPTKDM4EKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3892734-B1 SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2024-08-28 EP disclosed
EP-3892734-A1 SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION Ludwig-Maximilians-Universität München (DE) 2021-10-13 EP disclosed
EP-3892734-A1 SCREENING METHODS AND THERAPEUTIC APPLICATIONS BASED ON BACTERIAL MOTILITY INHIBITION Ludwig-Maximilians-Universität München (DE) 2021-10-13 EP disclosed
EP-2145884-B1 INDOLEDIONE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
US-8106086-B2 Indoledione derivative MSD K.K. (JP) 2012-01-31 US disclosed
CN-101343251-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-11-09 CN disclosed
CN-101343250-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-09-21 CN disclosed
CN-101805291-A 1-(4-isopropylbenzene-yl)-3-methyl-5-pyrazolone, preparation method and application thereof UNIV NORTHWESTERN 2010-08-18 CN disclosed
CN-101805291-A 1-(4-isopropylbenzene-yl)-3-methyl-5-pyrazolone, preparation method and application thereof UNIV NORTHWESTERN 2010-08-18 CN disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
CN-101343250-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-101342169-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-101343251-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-100423721-C Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2008-10-08 CN disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
CN-1444477-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2003-09-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALDH1A1 1012/4885MAPT 4627/4885KDM4E 3202/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALDH1A1 1012/4885MAPT 4627/4885KDM4E 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.